Substance and claimed effects

Broccoli sprouts are 3-to-5-day-old Brassica oleracea seedlings, eaten raw, used as a concentrated dietary source of glucoraphanin — the glucosinolate precursor of sulforaphane (1-isothiocyanato-4-(methylsulfinyl)butane). Sprouts at this stage contain roughly 10–100× the glucoraphanin of mature broccoli florets on a per-gram fresh-weight basis Fahey 1997. When the sprout's cell walls are ruptured (chewing, blending, crushing), the endogenous plant enzyme myrosinase hydrolyses glucoraphanin to sulforaphane, the bioactive isothiocyanate. Sulforaphane is the most potent known dietary inducer of the Keap1/Nrf2/ARE pathway, which transcriptionally upregulates a coordinated battery of phase II detoxification and antioxidant enzymes — glutathione S-transferases (GSTs), NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1), and glutamate-cysteine ligase Kensler 2013. This entry covers (i) detoxification and accelerated urinary clearance of airborne carcinogens and irritants, (ii) blood-pressure reduction and broader cardiometabolic effects, (iii) oxidative-stress and inflammatory-marker reductions, (iv) preparation and bioavailability (myrosinase status, heat, chewing), and (v) cancer-related chemoprevention signals (gastric, prostate). Population scope: typical adults; effects are largest in those with cardiometabolic disease or high pollutant/carcinogen exposure.

Evidence by addressing question

Mechanism

Glucoraphanin (4-methylsulfinylbutyl glucosinolate) is a stable, water-soluble precursor stored in vacuoles of intact Brassica tissue. Myrosinase (β-thioglucosidase), compartmentalised separately in myrosin cells, is released on tissue damage and cleaves the thioglucoside bond; the resulting unstable aglycone rearranges (in neutral pH, with iron and epithiospecifier protein absent) to sulforaphane, the isothiocyanate Fahey 1997. Sulforaphane is electrophilic at its central carbon and reacts with reactive cysteine thiols on Keap1, the cytosolic repressor that normally targets Nrf2 for ubiquitin-mediated degradation. Once Keap1 is modified, Nrf2 escapes degradation, accumulates, translocates to the nucleus, and binds the antioxidant response element (ARE) upstream of ~200 cytoprotective genes — including GSTs, NQO1, HO-1, UDP-glucuronosyltransferases, γ-glutamyl-cysteine ligase, thioredoxin reductase, and several efflux transporters Kensler 2013. The functional consequence is a transient (~24-48h per dose) upregulation of conjugation chemistry that converts electrophilic carcinogens (benzene oxide, acrolein, polycyclic aromatic hydrocarbons, aflatoxin-epoxide) into glutathione or mercapturic-acid conjugates excreted in urine. The same pathway dampens NF-κB-driven inflammatory transcription and raises baseline antioxidant capacity. Sulforaphane is not stored — its biological footprint is the wave of induced enzyme expression, which decays over 1–3 days as transcripts return to baseline, so daily intake is the relevant cadence.

Evidence — air-pollutant and carcinogen clearance

The strongest direct human evidence is from the Johns Hopkins/Qidong collaboration. In a 12-week parallel-group randomised trial in He-He Township, Qidong, China (n = 291, one of the most polluted rural air sheds studied), participants drank a daily broccoli-sprout beverage delivering 600 µmol glucoraphanin + 40 µmol sulforaphane vs. matched placebo. Urinary excretion of the mercapturic acid of benzene (S-phenylmercapturic acid) rose 61% over baseline beginning on day 1 and sustained through week 12; the α,β-unsaturated carbonyl acrolein rose 23% durably Egner 2014. A subsequent crossover bioavailability study in the same cohort confirmed that a sprout beverage containing pre-formed sulforaphane reached higher peak plasma concentrations than a glucoraphanin-only beverage relying on colonic microbial conversion, establishing the importance of either active plant myrosinase or pre-hydrolysed sulforaphane in the dose Egner 2011. The same Qidong programme had earlier shown reduced urinary aflatoxin-DNA adducts and phenanthrene tetraols in glucoraphanin-rich broccoli-sprout interventions, consistent with phase II induction acting on multiple electrophilic carcinogen classes. The biological cascade — Nrf2 activation, GST/NQO1 upregulation, faster urinary conjugate excretion — is internally consistent and replicated across populations and analytes.

Evidence — blood pressure and cardiometabolic markers

A 2022 systematic review and meta-analysis of ten clinical trials (publications 2004–2019) of sulforaphane-yielding broccoli-sprout preparations in cardiometabolic populations (diabetes, hypertension, fatty liver, with two healthy-volunteer trials) found pooled reductions of 10.9 mmHg systolic (95% CI −17.0 to −4.86) and 6.95 mmHg diastolic (95% CI −10.6 to −3.28) blood pressure Li 2022. Effect sizes were largest in hypertensive and diabetic subgroups; healthy normotensive trials showed smaller, less consistent BP movement. Multiple smaller RCTs in type 2 diabetes have shown reductions in fasting insulin and HOMA-IR with 10 g/day sprout powder over 4 weeks Bahadoran 2012, and reductions in serum hs-CRP and IL-6 at the same dose Mirmiran 2012. The mechanism candidates are Nrf2-mediated reduction in vascular oxidative stress, suppression of NF-κB-driven endothelial inflammation, and possibly direct effects on insulin signalling via redox-sensitive kinases. Trial sample sizes are small (typically 40–80), durations short (4–12 weeks), and most positive trials come from a small number of research groups — replication in larger, longer trials by independent groups is still pending.

Evidence — oxidative stress and inflammation

Pre-clinical work and the trials above consistently show GSH:GSSG ratio increases, lower urinary 8-hydroxy-2'-deoxyguanosine (oxidative DNA damage marker), and lower hs-CRP and IL-6 after 4–12 weeks of regular intake at sulforaphane equivalents of 25–200 µmol/day Mirmiran 2012. A notable negative result: a US multi-centre RCT in moderate-to-severe COPD found no induction of Nrf2 target gene transcripts (NQO1, AKR1C1, HO-1) in bronchial epithelium or alveolar macrophages after 4 weeks of 25 or 150 µmol/day sulforaphane Wise 2016. The likeliest explanations: severe COPD lung tissue may have impaired Nrf2 responsiveness (chronic oxidative stress, smoking history); the dosing formulation differed (stabilised pre-formed sulforaphane, not sprout beverage); the measurement site (lung tissue) is downstream of the systemic exposure measured in Qidong (urinary mercapturic acids).

Evidence — cancer-related chemoprevention

The strongest chemopreventive signal is for upper-GI and detoxification-relevant cancers. In a small RCT in Japan, 70 g/day fresh broccoli sprouts for 8 weeks reduced Helicobacter pylori colonisation markers (urea breath test, stool antigen) and gastritis indices (pepsinogen ratio) vs. alfalfa-sprout control; effects reverted within 2 months of stopping Yanaka 2009. A multicentre French RCT in 78 men with rising PSA after radical prostatectomy gave 60 mg/day stabilised sulforaphane for 6 months: the primary endpoint (log PSA slope) was not met, but PSA doubling time was prolonged 86% (28.9 vs 15.5 months) and the proportion with >20% PSA rise at 6 months was lower in the sulforaphane arm (44.4% vs 71.8%) Cipolla 2015. These are intermediate biomarkers, not clinical-endpoint trials.

Evidence — neuropsychiatric (autism)

An 18-week randomised double-blind PNAS trial in 44 young men (13–27) with moderate-to-severe ASD found sulforaphane (50–150 µmol/day, weight-dependent) produced clinically meaningful improvements on Aberrant Behavior Checklist, Social Responsiveness Scale, and Clinical Global Impression-Improvement vs. placebo; effects reverted on discontinuation Singh 2014. The proposed mechanism connects oxidative stress, mitochondrial dysfunction, and neuroinflammation observed in subsets of ASD with Nrf2-mediated cytoprotection. This is a narrow indication and does not generalise to focus/mood claims in typical adults.

Protocol — dose, preparation, myrosinase

Active doses across human trials cluster around 50–200 µmol/day sulforaphane equivalents. In food terms: ~1/2 cup (40–50 g) of fresh broccoli sprouts well-chewed delivers roughly 50–100 µmol sulforaphane, depending on cultivar and seed glucoraphanin content (highly variable, ~10× between low and high cultivars; Calabrese and BroccoSprouts cultivars selected for high glucoraphanin). The Qidong beverage delivered 600 µmol/day glucoraphanin + 40 µmol/day sulforaphane.

Myrosinase is the bottleneck. Mean bioavailability of glucoraphanin lacking active myrosinase is ~10% (relies on gut microbial thioglucosidase, highly variable interpersonally); with active myrosinase in the dose, bioavailability rises to ~40–50% Atwell 2015. Practical consequences: (i) fresh raw sprouts contain abundant active myrosinase — chewing or blending suffices; (ii) cooked mature broccoli has been heat-inactivated for myrosinase and yields much less sulforaphane unless an exogenous source is added (mustard powder, daikon radish, horseradish, wasabi — all contain heat-stable or freshly-active myrosinase); (iii) commercial broccoli-extract supplements vary wildly — those marketed as "glucoraphanin only" without active myrosinase or pre-formed sulforaphane perform worst. Brief blanching of sprouts at ~60°C for ~10 min has been shown to deactivate epithiospecifier protein (which otherwise diverts hydrolysis to inactive sulforaphane-nitrile) while preserving myrosinase, increasing sulforaphane yield — but most users eat sprouts raw and the marginal gain is small.

Contraindications and safety

Sprouts in general are a recognised source of foodborne illness — Salmonella, E. coli O157:H7, and Listeria outbreaks have been traced to sprout seed contamination across two decades. FDA regulations now require seed lot treatment and testing, but household sprouting carries irreducible residual risk: warm, humid germination conditions favour pathogen growth on any seed-borne contamination FDA 2022. CDC and FDA advise immunocompromised individuals, pregnant women, young children, and older adults to avoid raw sprouts; cooked sprouts are safe but lose much of the sulforaphane yield (myrosinase inactivation). The thiocyanate/goitrogen concern is largely theoretical: a dedicated 12-week thyroid-safety RCT of the Qidong sprout beverage found no effect on TSH, fT4, thyroglobulin, or anti-thyroid antibodies Yagishita 2019. Common mild side effects at high supplemental doses are gas, bloating, and loose stools (sulforaphane and other isothiocyanates are mild gut irritants). Theoretical interactions with CYP-substrate drugs exist (sulforaphane modulates phase I in vitro) but no clinically significant interactions have been documented.

Misconceptions

(i) "Mature broccoli is the same as broccoli sprouts" — false; sprout glucoraphanin content is 10–100× higher per gram fresh weight Fahey 1997, and cooked mature broccoli has near-zero myrosinase. (ii) "Supplements are equivalent to fresh sprouts" — bioavailability ranges from ~10% (glucoraphanin only) to ~50% (glucoraphanin + myrosinase or pre-formed sulforaphane) Atwell 2015; the label often does not say which formulation. (iii) "More is always better" — the Nrf2 system saturates at moderate doses; trials at 200 µmol/day are not consistently better than 50–100 µmol/day. (iv) "Sulforaphane is stable in pills" — it is reactive and slowly degrades; reputable supplements use stabilised forms or deliver glucoraphanin + myrosinase to generate sulforaphane in vivo. (v) "Sulforaphane causes thyroid problems" — not supported in the dedicated 12-week RCT at intervention doses Yagishita 2019.

Practicalities and population variability

Home sprouting: organic broccoli sprouting seed (~$15 for 0.5 lb, ~3-month supply), a wide-mouth quart mason jar with a screen lid, ~3–5 days from seed to harvest. Soak 2 tbsp dry seed overnight, drain, rinse twice daily, harvest at day 3–5. Cost per serving is on the order of $0.20–0.50. Commercial fresh sprouts cost $3–6/100 g; supplements with active myrosinase or pre-formed sulforaphane cost $20–40/month. Cultivar matters: glucoraphanin content varies ~10× between cultivars Fahey 1997, so seed source matters. Population variability in response is high: GSTM1/GSTT1 genotype (~50% of the population lack functional GSTM1) alters sulforaphane metabolism kinetics — null genotype individuals excrete conjugates faster, which may either increase or decrease tissue exposure depending on the endpoint. Baseline pollutant exposure is the largest determinant of detectable detoxification benefit: the Qidong effect sizes will not transplant directly to a low-pollutant suburb. Baseline BP and inflammation determine the cardiometabolic effect size: normotensive healthy adults will see smaller changes than hypertensives.

Stakes

For a typical urban or pollution-exposed adult, skipping this entry means lifelong baseline exposure to ambient electrophilic carcinogens (benzene from traffic, polycyclic aromatic hydrocarbons from cooking smoke and combustion, acrolein from frying oils and wildfire smoke) cleared at the body's default conjugation rate. For cardiometabolic populations, it means foregoing a small but real adjunct intervention to BP and inflammation control. Neither stake is catastrophic individually; the case is cumulative-exposure-over-decades.

Payoff

Within 24 hours of the first dose, urinary excretion of benzene and acrolein conjugates rises measurably and stays elevated for the duration of regular intake Egner 2014. Within 4–12 weeks at clinical doses in cardiometabolic populations, blood pressure drops ~10/7 mmHg Li 2022, hs-CRP and IL-6 fall Mirmiran 2012. Cumulative effects over years are inferred from cruciferous-vegetable epidemiology: the cruciferous subgroup of fruit/vegetable intake is associated with the steepest cardiovascular-mortality dose-response curve in pooled cohort analyses Aune 2017.

Credibility range

Optimist case. Sulforaphane is the most potent dietary Nrf2 inducer ever characterised, with a well-mapped mechanism, multiple replicated human trials showing acute carcinogen detoxification (Egner/Kensler, replicated across populations), strong BP and inflammatory-marker effects in cardiometabolic populations (Li 2022 meta-analysis), and a credible mechanism for cumulative cancer chemoprevention. Aflatoxin biomarker work in Qidong contributed to one of the largest documented reductions in regional liver-cancer incidence in modern epidemiology. Cruciferous-vegetable epidemiology, of which broccoli sprouts are the most concentrated form, is the most consistent vegetable subgroup signal for cardiovascular mortality. Home sprouting is essentially free, daily, and bioavailability-optimal. For anyone with substantial pollutant exposure or borderline hypertension, this is one of the highest-value single dietary additions available.

Skeptic case. The trial base is small, durations are short (mostly 4–12 weeks), most positive trials cluster in a small network of investigators (the Hopkins/Talalay/Fahey lineage and a few Iranian groups), and large independent replication is thin. The largest US negative trial (COPD, Wise 2016) found no Nrf2 induction at supplemental doses. The prostate trial primary endpoint failed; PSA doubling time is a soft secondary. The autism finding is intriguing but the sample was tiny (n=29 active) and downstream replications have been mixed. Bioavailability is so format-dependent that supplement results in the market vary by an order of magnitude, and labelling is poor. Cardiovascular-mortality reduction from broccoli sprouts specifically — as opposed to "eating vegetables" generally — has never been tested in a clinical-endpoint trial and never will be (would need ~30 years and ~50,000 participants). Sprouts carry real foodborne-pathogen risk for vulnerable populations.

Author's call. The mechanism and the acute detoxification effect are settled science; the BP and inflammation effects in cardiometabolic populations are likely real but need larger independent replication; the cancer chemoprevention claim is biologically plausible and supported by intermediate-biomarker evidence but not by clinical-endpoint trials. For a typical adult, the right framing is: cheap, low-effort daily addition with one truly settled benefit (faster clearance of common ambient electrophilic toxicants), one probably-real benefit in subgroups (BP and inflammation in cardiometabolic populations), and a credible-but-unproven long-term cancer-prevention bet. Evidence rating: 3. Controversy: 2 (most disagreement is about magnitude in healthy adults, not about whether the mechanism works).

Stakeholder and incentive map

• Academic/public-health drivers: The Johns Hopkins Brassica Chemoprotection Laboratory (Talalay, Fahey, Kensler) and downstream collaborators have shaped this field for 25 years; they are the most credible voice and have generally been conservative on claim inflation, but their continued funding depends on the field's continued relevance.
• Supplement industry: Avmacol, Prostaphane, BroccoMax, and many private-label glucoraphanin/sulforaphane supplements. Quality varies wildly; many do not declare myrosinase status; price markup is high vs. home-grown sprouts.
• Functional-food/wellness influencers: Rhonda Patrick has been the most visible amplifier in the lay-science space; the message has generally been accurate but the volume can read as overclaim relative to trial base.
• Sprout-seed industry: Small, niche; primary safety incentive is correctly aligned (avoiding outbreak liability).
• Skeptic/counter-incentive: Mainstream nutrition guidelines (USDA, NHS) treat broccoli sprouts as a vegetable, not as a singled-out intervention. No professional body has issued a specific recommendation. No drug company has an interest in advancing or attacking the field.

Population variability

• Genotype: GSTM1/GSTT1 null genotypes (~50% / ~20% of populations) excrete sulforaphane conjugates faster — possibly altering tissue exposure for any given dose.
• Baseline exposure: Effect of detoxification benefit scales with pollutant load. High-traffic urban dwellers, wildfire-smoke regions, smokers (active and second-hand), and high-PAH-diet populations gain most.
• Cardiometabolic baseline: Hypertensives and diabetics show the largest BP and inflammation effects; normotensive healthy adults see smaller, less consistent changes.
• Gut microbiome: For glucoraphanin-only formulations (no plant myrosinase), microbial thioglucosidase activity is the rate-limiting step; this varies widely by diet and antibiotic history.
• Pregnancy/breastfeeding: Food-amount intake is presumed safe; high-dose supplementation has not been studied. Sulforaphane-NAC transfers into breast milk at dietary-relevant levels.
• Immunocompromised, pregnant, very young, very old: Raw sprouts carry foodborne-pathogen risk; cooked sprouts lose most of the sulforaphane yield. Glucoraphanin + myrosinase supplements are the practical workaround.

Knowledge gaps

• Large independent BP-outcomes RCT (n > 500, 6–12 months, independent of the existing investigator network) has not been run.
• No clinical-endpoint cancer-prevention trial; intermediate biomarker work is the ceiling of evidence and likely will remain so.
• Optimal dosing across genotype subgroups is unmapped (GSTM1/GSTT1 stratification would clarify whether non-null individuals need higher doses).
• Long-term (years) safety of supplemental high-dose sulforaphane has not been systematically characterised; food-amount sprout intake has implicit safety from cruciferous-vegetable epidemiology.
• The COPD negative result deserves replication in less severe disease and with different formulations to clarify whether the lung-tissue Nrf2 response is genuinely refractory or formulation-specific.
• Stability and bioavailability of off-the-shelf supplements vs label claims has been spot-checked but not systematically audited.

Scope honesty. The brief named four consequences (phase II enzyme induction, oxidative-stress and inflammation markers, blood pressure, air-pollutant and carcinogen clearance). All four are covered in the article body. The autism trial signal (Singh 2014) is mentioned in research and flagged in out-of-scope as a separate-entry candidate; it does not generalise to focus/mood claims for typical adults and would mis-signal if included in meta scoring.

Rating calls worth flagging.

• I kept focus, energy, mood, and sleep at 0. The temptation was 1 ("downstream of lower inflammation") — the rating framework's instruction to "score 0 freely" and "be honest about zeros" cut harder than the temptation. No felt-experience evidence in healthy adults supports them.
• evidence: 3 is the call I was most pulled on. The acute carcinogen-detoxification effect is genuinely settled (replicated in independent Qidong trials, mechanism mapped). The BP meta-analysis is striking. But the trial base clusters in a small investigator network, the COPD negative is real, and the prostate primary endpoint missed. 3 ("small or preliminary studies with a plausible mechanism; worth trying") is more honest than 4.
• applicability: 4 reflects that air-pollutant exposure is genuinely universal and cardiometabolic risk affects most adults at some point. Not 5 because the largest effect size lives in clinical subgroups.
• contraindications: ["pregnancy"] — included because of the raw-sprout foodborne-illness risk for pregnant women (CDC/FDA guidance); the sulforaphane itself appears safe at food-level intake and crosses into breast milk at dietary-relevant levels. Did not add breastfeeding because the food-amount evidence is reassuring; high-dose supplementation in lactation is an open question I noted in research.

Hard decisions during the write. Whether to pitch this as a relief lever ("the toxins leave faster") or as cardiometabolic adjunct ("BP and inflammation"). Went with relief in the dek/tagline because (a) air-pollutant exposure is universal where BP elevation is not, and (b) the detoxification evidence is the cleanest signal. Cardiometabolic story carries the highlights paragraph and the evidence section.

Separate-entry candidates.

• Cruciferous vegetables (whole-family, not concentrated) — the epidemiology lives there.
• Sulforaphane in autism — narrow population, distinct evidence base, distinct mechanism story.
• Mustard powder / daikon / wasabi as exogenous myrosinase sources for cooked cruciferous meals — a separate practical entry worth writing.
• Air-quality interventions (HEPA, N95 on smoke days) — the upstream side of the same exposure story.

Future link candidates. Once entries exist: cruciferous vegetables, blood pressure (overview), air quality / HEPA filtration, NRF2 pathway as a unifying mechanism across multiple food entries.

Dream narrative tier. Computed overall ~28, below the 40 obligatory threshold. Wrote a brief relief-lever narrative anyway because the honest hook (something measurable happening in the background you cannot feel) genuinely supports it, and skipping it would have left the dek flatter than it should be. The dek and tagline carry it lightly; no marketing-word escalation was needed.